HRP20210998T1 - Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met - Google Patents
Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met Download PDFInfo
- Publication number
- HRP20210998T1 HRP20210998T1 HRP20210998TT HRP20210998T HRP20210998T1 HR P20210998 T1 HRP20210998 T1 HR P20210998T1 HR P20210998T T HRP20210998T T HR P20210998TT HR P20210998 T HRP20210998 T HR P20210998T HR P20210998 T1 HRP20210998 T1 HR P20210998T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- met
- treatment
- mutation
- met inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 22
- 239000003112 inhibitor Substances 0.000 title claims 14
- 230000035772 mutation Effects 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 claims 21
- XYDNMOZJKOGZLS-NSHDSACASA-N 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine Chemical group N1=C2N([C@H](C3=CN4C=CN=C4C=C3)C)N=NC2=NC=C1C=1C=NN(C)C=1 XYDNMOZJKOGZLS-NSHDSACASA-N 0.000 claims 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 5
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 5
- 229950003500 savolitinib Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
Claims (10)
1. Inhibitor c-Met za uporabu u liječenju karcinoma, gdje je karcinom naznačen time što ima mutaciju MET 1195 i gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
2. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 1, naznačen time što je mutacija MET 1195 supstitucija aminokiseline.
3. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 2, gdje je karcinom naznačen time što ima mutaciju MET L1195F.
4. Inhibitor c-Met za uporabu u liječenju karcinoma prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je karcinom rak pluća, rak želuca ili papilarni karcinom bubrežnih stanica.
5. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 4, naznačen time što je karcinom papilarni karcinom bubrežnih stanica.
6. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 5, naznačen time što je karcinom papilarni karcinom bubrežnih stanica tipa II.
7. Inhibitor c-Met za uporabu u liječenju karcinoma prema patentnom zahtjevu 1, gdje je karcinom papilarni karcinom bubrežnih stanica tipa II koji je naznačen time što ima mutaciju MET L1195F, a savolitinib, ili njegova farmaceutski prihvatljiva sol, se primjenjuje u farmaceutskom pripravku koji sadrži 600 mg savolitiniba u obliku njegove slobodne baze, uz doziranje jednom dnevno.
8. Postupak pregleda pacijenata s karcinomom radi utvrđivanja njihove prikladnosti za liječenje inhibitorom c-Met, koji obuhvaća analizu reprezentativnog uzorka karcinoma pacijenta in-vitro kako bi se utvrdilo da li je karcinom naznačen time što ima mutaciju MET 1195, gdje ako se utvrdi da je karcinom kod pacijenta naznačen time što ima mutaciju MET 1195, pacijent je pogodan za liječenje inhibitorom c-Met, te gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
9. Postupak prema patentnom zahtjevu 8, koji obuhvaća analizu reprezentativnog uzorka pacijentovog karcinoma in-vitro kako bi se utvrdilo da li je karcinom naznačen time što ima mutaciju MET L1195F, gdje ako se utvrdi da je karcinom kod pacijenta naznačen time što ima mutaciju MET L1195F, pacijent je pogodan za liječenje inhibitorom c-Met, te gdje je inhibitor c-Met savolitinib ili njegova farmaceutski prihvatljiva sol.
10. Postupak prema bilo kojem od patentnih zahtjeva 8 ili 9, naznačen time što je karcinom papilarni karcinom bubrežnih stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616116.8A GB201616116D0 (en) | 2016-09-22 | 2016-09-22 | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| EP17777211.8A EP3515418B1 (en) | 2016-09-22 | 2017-09-21 | Use of c-met inhibitors to treat cancers harbouring met mutations |
| PCT/EP2017/073894 WO2018055029A1 (en) | 2016-09-22 | 2017-09-21 | Use of c-met inhibitors to treat cancers harbouring met mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210998T1 true HRP20210998T1 (hr) | 2021-09-17 |
Family
ID=57539720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210998TT HRP20210998T1 (hr) | 2016-09-22 | 2021-06-24 | Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190282570A1 (hr) |
| EP (1) | EP3515418B1 (hr) |
| JP (1) | JP7065858B2 (hr) |
| CN (1) | CN109789108A (hr) |
| CY (1) | CY1124668T1 (hr) |
| DK (1) | DK3515418T3 (hr) |
| ES (1) | ES2880085T3 (hr) |
| GB (1) | GB201616116D0 (hr) |
| HR (1) | HRP20210998T1 (hr) |
| HU (1) | HUE054765T2 (hr) |
| LT (1) | LT3515418T (hr) |
| PL (1) | PL3515418T3 (hr) |
| PT (1) | PT3515418T (hr) |
| RS (1) | RS62084B1 (hr) |
| SI (1) | SI3515418T1 (hr) |
| TW (1) | TWI784969B (hr) |
| WO (1) | WO2018055029A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220008419A1 (en) * | 2018-11-14 | 2022-01-13 | Kanazawa Medical University | Pharmaceutical composition for treating diffuse-type gastric cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| AU2006323027B2 (en) * | 2005-12-05 | 2012-08-02 | Pfizer Products Inc | Method of treating abnormal cell growth |
| CA2646048A1 (en) * | 2006-03-30 | 2007-11-08 | Novartis Ag | Compositions and methods of use for antibodies of c-met |
| LT3795573T (lt) | 2009-12-31 | 2022-11-10 | Hutchison Medipharma Limited | Tam tikri triazolopirazinai, jų sudėtis ir jų panaudojimo būdai |
-
2016
- 2016-09-22 GB GBGB1616116.8A patent/GB201616116D0/en not_active Ceased
-
2017
- 2017-09-21 PT PT177772118T patent/PT3515418T/pt unknown
- 2017-09-21 PL PL17777211T patent/PL3515418T3/pl unknown
- 2017-09-21 LT LTEP17777211.8T patent/LT3515418T/lt unknown
- 2017-09-21 SI SI201730818T patent/SI3515418T1/sl unknown
- 2017-09-21 TW TW106132358A patent/TWI784969B/zh active
- 2017-09-21 HU HUE17777211A patent/HUE054765T2/hu unknown
- 2017-09-21 CN CN201780057297.7A patent/CN109789108A/zh active Pending
- 2017-09-21 DK DK17777211.8T patent/DK3515418T3/da active
- 2017-09-21 WO PCT/EP2017/073894 patent/WO2018055029A1/en unknown
- 2017-09-21 ES ES17777211T patent/ES2880085T3/es active Active
- 2017-09-21 US US16/335,697 patent/US20190282570A1/en not_active Abandoned
- 2017-09-21 RS RS20210854A patent/RS62084B1/sr unknown
- 2017-09-21 JP JP2019536698A patent/JP7065858B2/ja active Active
- 2017-09-21 EP EP17777211.8A patent/EP3515418B1/en active Active
-
2021
- 2021-06-24 HR HRP20210998TT patent/HRP20210998T1/hr unknown
- 2021-07-13 CY CY20211100624T patent/CY1124668T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3515418T (lt) | 2021-07-26 |
| CY1124668T1 (el) | 2022-07-22 |
| EP3515418B1 (en) | 2021-04-14 |
| JP7065858B2 (ja) | 2022-05-12 |
| CN109789108A (zh) | 2019-05-21 |
| TW201909916A (zh) | 2019-03-16 |
| US20190282570A1 (en) | 2019-09-19 |
| DK3515418T3 (da) | 2021-07-12 |
| SI3515418T1 (sl) | 2021-08-31 |
| ES2880085T3 (es) | 2021-11-23 |
| PT3515418T (pt) | 2021-07-13 |
| WO2018055029A1 (en) | 2018-03-29 |
| RS62084B1 (sr) | 2021-08-31 |
| GB201616116D0 (en) | 2016-11-09 |
| HUE054765T2 (hu) | 2021-09-28 |
| TWI784969B (zh) | 2022-12-01 |
| EP3515418A1 (en) | 2019-07-31 |
| PL3515418T3 (pl) | 2021-12-13 |
| JP2019529554A (ja) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | A review on curability of cancers: more efforts for novel therapeutic options are needed | |
| EP3222278B1 (en) | Use of azelnidipine in preparing medicinal composition for treating cancers | |
| Novello et al. | Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer | |
| Yap et al. | Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers | |
| HRP20231478T1 (hr) | Csf1r inhibitori za primjenu u liječenju raka | |
| HRP20201737T1 (hr) | Metoda za liječenje tumora, farmaceutski sastav i pribor za lijekove | |
| JP2019532051A5 (hr) | ||
| JP2015536964A5 (hr) | ||
| JP2016041733A5 (hr) | ||
| PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| Van Wynsberghe et al. | Nephrotoxicity of anti-angiogenic therapies | |
| Schmidt et al. | Targeting protein synthesis in colorectal cancer | |
| JP2013501224A5 (hr) | ||
| JP2016520528A5 (hr) | ||
| Blomberg et al. | Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review | |
| Malakar et al. | Theophylline release behavior from hard gelatin capsules containing hydrophilic polymeric matrices. | |
| JP2014525454A5 (hr) | ||
| HRP20210998T1 (hr) | Uporaba inhibitora c-met za liječenje karcinoma koji su utočište za mutacije met | |
| WO2016140933A3 (en) | Immediate release soluble ibuprofen compositions | |
| Kacan et al. | Antitumor activity of sorafenib on colorectal cancer | |
| Asahina et al. | An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors | |
| JP2017517520A5 (hr) | ||
| Mei et al. | The positive clinical therapeutically effects of Escin on advanced thyroid cancer | |
| De Rubis et al. | Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma | |
| Kim et al. | Phase II study of induction chemotherapy with docetaxel, capecitabine, and cisplatin plus bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis |